Orexin-1 Receptor Antagonist Compounds With Selective CNS Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that are potent inhibitors of the orexin-1 (OX1) receptor with selectivity over the orexin-2 (OX2) receptor, exhibiting increased residency time at OX1 receptors, favorable pharmaceutical properties, and effective therapeutic benefits for treating addictive disorders and CNS disorders without affecting sleep-wake cycles.
Innovation Solution
Development of compounds, such as N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-[(2S)-1-{[5-(trifluoro methyl)pyrazin-2-yl]amino}propan-2-yl]pyridine-2-carboxamide, which selectively inhibit OX1 receptors, have favorable properties like solubility, metabolic stability, and brain penetration, and are designed to prolong receptor occupancy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dual OX1 and OX2 antagonists are used to treat sleep disorders, then sleep-wake cycle regulation is improved, but selectivity for OX1 receptor inhibition deteriorates
Solution Approach 1:
The patent segments the receptor antagonism function by designing compounds that selectively target only the OX1 receptor while excluding OX2 receptor interaction. This is achieved through specific molecular structure design (formula I compounds with particular substituent patterns) that creates steric and electronic complementarity only with OX1 receptor binding site, thereby achieving therapeutic efficacy for addictive disorders without dual receptor modulation
Solution Approach 2:
The invention applies local quality by optimizing specific regions of the molecule (R1-R6 substituents on the pyridine core, heterocyclic group selection) to enhance OX1 receptor binding affinity and selectivity. The structural modifications at specific positions create localized interactions that differentiate OX1 from OX2 receptor binding, ensuring selective inhibition of OX1-mediated addictive behaviors while preserving OX2 function
2Duration of action of moving object
If compound residency time at OX1 receptor is increased to extend duration of action, then therapeutic duration is improved, but compound complexity increases
Solution Approach 1:
The patent employs preliminary action by designing compounds with pre-optimized pharmacokinetic properties including metabolic stability features and brain penetration characteristics built into the core structure. The molecular design incorporates elements that predispose the compound for extended receptor residency and favorable ADME properties from the outset, rather than requiring complex post-synthesis modifications
Solution Approach 2:
The invention utilizes parameter changes by systematically varying molecular parameters (hydrophobicity, molecular weight, heteroatom content, substituent electronics) to optimize the balance between receptor binding duration and metabolic stability. These controlled parameter adjustments extend duration of action while maintaining reasonable molecular complexity through rational design rather than exhaustive structural exploration
3Reliability
If compound solubility and metabolic stability are optimized for favorable pharmaceutical properties, then drug-likeness is improved, but brain penetration capability may deteriorate
Solution Approach 1:
The patent applies parameter changes by carefully balancing lipophilicity (logP), molecular weight, and hydrogen bonding capacity within optimal ranges that simultaneously satisfy solubility, metabolic stability, and blood-brain barrier penetration requirements. The core pyridine-triazole structure with specific substituent patterns achieves this multi-parameter optimization, ensuring favorable pharmaceutical properties while maintaining adequate CNS exposure for treating addictive disorders
Solution Approach 2:
The invention employs composite material principles by combining heterocyclic moieties (pyridine, triazole, pyrazine) with specific substituent groups to create a composite molecular structure that integrates multiple functional properties. This composite design achieves synergistic effects where the core structure provides metabolic stability and solubility while peripheral substituents enhance brain penetration and receptor selectivity
4Ease of repair
If selective OX1 inhibition is achieved to treat addictive disorders, then therapeutic specificity is improved, but off-target effects on other CNS functions may worsen
Solution Approach 1:
The patent segments the orexin receptor family functionality by creating compounds that exclusively inhibit OX1 receptor while leaving OX2 receptor intact. This functional segmentation is achieved through molecular structure design that exploits subtle differences in OX1 versus OX2 binding sites, thereby treating addictive behaviors through OX1 selectivity while preserving OX2-mediated sleep-wake regulation and other CNS functions
Data Source
AI summary
The present invention relates to compounds that are antagonists of the orexin-1 receptor. The compounds have the structural formula (I) defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.